Saltar al contenido
Merck

SML2281

Sigma-Aldrich

BAY 60-2770

≥98% (HPLC)

Sinónimos:

4-[((4-Carboxy-butyl)-{2-[5-fluoro-2-(4′-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-ethyl}-amino)-methyl]-benzoic acid, 4-[[(4-Carboxybutyl)[2-[5-fluoro-2-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C35H33F4NO5
Número de CAS:
Peso molecular:
623.63
Código UNSPSC:
12352200
NACRES:
NA.77

Análisis

≥98% (HPLC)

formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

FC1=CC=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(CCN(CC4=CC=C(C(O)=O)C=C4)CCCCC(O)=O)=C1

Acciones bioquímicas o fisiológicas

BAY 60-2770 is a potent and selective soluble guanylyl cyclase (sGC) heme-independent activator that protects sGC from heme oxidation in smooth muscle tissues. BAY 60-2770 provides cardioprotection and limits the infarct size in rat ischaemia-reperfusion model. Also BAY 60-2770 Ameliorates of urethra dysfunction in high-fat fed obese mice.
Structurally, BAY 60-2770 comprises fluoro and trifluoromethyl moieties. It stimulates in vitro expressed α2/β1 isoform of nitric oxide sensitive guanylyl cyclase (NOsGC). BAY 60-2770 is reported to be effective in treating liver fibrosis and in lowering arterial pressures (both pulmonary and systemic) in animal studies. It elicits anti-aggregating and anti-adhesive effects on platelets and may have therapeutic potential to treat atherothrombotic events.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Camila B Mendes-Silverio et al.
PloS one, 7(11), e47223-e47223 (2012-11-13)
Nitric oxide-independent soluble guanylyl cyclase (sGC) activators reactivate the haem-oxidized enzyme in vascular diseases. This study was undertaken to investigate the anti-platelet mechanisms of the haem-independent sGC activator BAY 60-2770 in human washed platelets. The hypothesis that sGC oxidation potentiates
Eduardo C Alexandre et al.
The Journal of pharmacology and experimental therapeutics, 349(1), 2-9 (2014-01-15)
Obesity has emerged as a major contributing risk factor for overactive bladder (OAB), but no study examined urethral smooth muscle (USM) dysfunction as a predisposing factor to obesity-induced OAB. This study investigated the USM relaxant machinery in obese mice and
Justin S Bice et al.
Cardiovascular research, 101(2), 220-228 (2013-11-22)
Guanylyl cyclase-cyclic guanosine monophosphate signalling plays an important role in endogenous cardioprotective signalling. The aim was to assess the potential of direct pharmacological activation and stimulation of soluble guanylyl cyclase, targeting different redox states of the enzyme, to limit myocardial
Alexander Kollau et al.
Molecular pharmacology, 93(2), 73-78 (2017-11-16)
Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 60-2770 are interesting therapeutic tools for the treatment of various cardiovascular pathologies. The drugs are supposed to preferentially stimulate oxidized or heme-depleted, but not native sGC.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico